Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept weight-based vs weight-banded dosing in PAH
NCT06664801Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 21
01
Overview
A Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started Nov 2024; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06664801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664801.